Fisher, B. A., Szanto, A., Ng, W., Bombardieri, M., Posch, M. G., Papas, A. S., Farag, A. M., Daikeler, T., Bannert, B., Kyburz, D., Kivitz, A. J., Carsons, S. E., Isenberg, D. A., Barone, F., Bowman, S. J., Espié, P., Floch, D., Dupuy, C., Ren, X., Faerber, P. M., Wright, A. M., Hockey, H., Rotte, M., Milojevic, J., Avrameas, A., Valentin, M., Rush, J. S., & Gergely, P. (2020). assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet, 2, e142–e152. http://access.bl.uk/ark:/81055/vdc_100101666096.0x000001